This whale alert can help traders discover the next big trading opportunities. Whales are entities w

NEW YORK, June 25, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

CORT resubmits relacorilant NDA for Cushing's syndrome, with updated analyses and data from multiple

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercia

New York, New York--(Newsfile Corp. - June 16, 2026) - Kuehn Law, PLLC, a shareholder litigation law

Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take

Corcept shares surge 42% in a month as relacorilant advances in Cushing's syndrome and Lifyorli appr

New data from CATALYST and MOMENTUM trials presented at American Diabetes Association's (ADA) 86

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discover

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercia

Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs

Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concent

Compare diversification strategies and see how each ETF's unique index focus shapes risk and return

On May 19, 2026, Corcept Therapeutics Incorporated (the "Company") learned that the United S

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercia

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and

Corcept stock jumps after the company announces plans to resubmit relacorilant's NDA for treating Cu

Top Wall Street analysts changed outlook on top names. See all analyst rating changes, including upg

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:COR

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercia

The consensus price target hints at a 43.3% upside potential for Corcept (CORT). While empirical res

Corcept raises 2026 revenue guidance after strong Korlym Q1 performance. New launches and pipeline p

UBS analyst Ashwani Verma upgrades Corcept Therapeutics (NASDAQ:CORT) from Neutral to Buy and rai

Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [rela

Needham analyst Rick Patel maintained a Buy rating. Steven Madden shares closed at $47.27 on Friday.

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:COR

Piper Sandler analyst David Amsellem maintains Corcept Therapeutics (NASDAQ:CORT) with a Overweig

Corcept Q1 loss meets estimates, while revenues miss. The company boosts 2026 outlook as new drug Li

Corcept Therapeutics Inc. (NASDAQ:CORT) shares are up on Friday as the company reported significant

Corcept shares rise after Phase 2 ALS data shows 87% lower death risk; earnings miss, revenue shortf

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery

Corcept Therapeutics (NASDAQ:CORT) raises FY2026 sales outlook from $900.000 million-$1.000 billion

Corcept Therapeutics (NASDAQ:CORT) reported quarterly losses of $(0.30) per share which missed the a

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery

Data demonstrate a 35 percent reduction in risk of deathLifyorli, in combination with nab-paclitaxel

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and

Wolfe Research analyst Kalpit Patel upgrades Corcept Therapeutics (NASDAQ:CORT) from Underperform

Top analysts change outlook for top names. Citigroup, Tigress Fin, Piper Sandler, Morgan Stanley, HC

U.S. stocks rose, with the Dow Jones gaining 350 points on Wednesday. AAR Corp (NYSE: AIR) saw a 10.

US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics sur

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:COR

U.S. stocks advanced Wednesday as oil prices fell on Iran diplomacy reports. Arm jumped 15%, while T